Formed in 2011, IAC works to support equitable access to health, with a focus on advocacy, policy change, and local production of essential medicines.
Since 2016, IAC’s advocacy has contributed to antiretroviral (ARV) price reductions and the establishment of drug price monitoring systems. In 2019, they collaborated with the presidential office to promote local ARV production and reduce reliance on state-owned pharmaceutical monopolies. In 2021, IAC joined other organizations in successfully advocating for a government use license on remdesivir and favipiravir for COVID-19 treatment.
IAC has participated in global advocacy for Indonesia to co-sponsor the TRIPS waiver. They continue to engage in free trade agreement (FTA) discussions, provide IP capacity-building, pursue patent oppositions, and promote government use licences and local production initiatives.